Free Newsletter
Generic Coregs are coming
Free newsletter via e-mail
Tools
The FDA gave its blessing to more than a dozen generic versions of GlaxoSmithKline's Coreg (aka carvedilol), used to treat a variety of cardiovascular problems including high blood pressure and heart failure. Now, Glaxo will have to share the $1.7 billion carvedilol market with the likes of Actavis, Apotex, Caraco, Dr. Reddy's, Ranbaxy, Sandoz, Teva, and Watson, among others. A total of 14 generics were approved.
Ironically, the generic labeling may differ from the brand-name version because, while the drug itself is no longer under patent, certain bits of the labeling are.
- see the FDA release
Related Articles:
Riled investors look for big changes at GSK. Report
Patent 'cliff' looms for Big Pharma. Report
More stories about FDA approval FDA Coreg Teva Pharmaceutical Ranbaxy Patent GlaxoSmithKline Generics
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
